Trending Market News
Standard Chartered announced plans on May 19, 2026, to cut more than 8,000 jobs, representing over 15% of its corporate functions workforce, as part of a strategic shift toward artificial intelligence and automation. CEO Bill Winters characterized the move as replacing 'lower-value human capital' with investment in AI technology rather than simple cost-cutting. The restructuring aims to create a simpler operating model while scaling AI applications across processes including client service and internal efficiency.
- The cuts affect approximately 8,000 of Standard Chartered's 52,000 support services employees, representing more than 15% of corporate functions roles
- CEO Bill Winters stated the changes involve 'job role reductions in favor of the machines' that will accelerate as AI adoption increases
- The bank plans to scale automation, advanced analytics and AI to streamline processes, improve decision-making and enhance both client service and operational efficiency
Forty major food and agriculture companies, including Carlsberg, Diageo, Nestle, and Mondelez, have signed a joint declaration to advance regenerative agriculture through SAI Platform's programme. The initiative aims to address climate change, biodiversity loss, and soil degradation while securing agricultural supply chains through collaborative industry-wide efforts.
- Signatories include major corporations such as ADM, McCormick, and Unilever, acknowledging that no single organization can drive the necessary systemic change alone
- SAI Platform's regenerative agriculture programme incorporates input from farmers, NGOs, and academics to align efforts across the entire supply chain
- The initiative emphasizes collaboration over isolated efforts to tackle environmental challenges including climate change, biodiversity loss, and soil degradation
Epic Games announced that its popular game 'Fortnite' has returned to global app stores, expressing confidence in its ongoing lawsuit against Apple over app store fees. The return comes after a nearly five-year ban, though the game remains unavailable on Australia's App Store as Apple continues enforcing developer terms a court found unlawful.
- Epic has been in a legal battle with Apple since 2020, challenging the tech giant's practice of charging up to 30% commission on in-app payments as violating U.S. antitrust rules
- 'Fortnite' is one of the world's most popular battle royale games with millions of daily players, though Epic announced layoffs earlier this year due to declining engagement from macroeconomic uncertainty
- Epic stated that 'governments around the world will not allow Apple junk fees to stand' once Apple is forced to disclose its costs in court proceedings
Deutsche Bank's London branch was fined £165,000 ($221,084) by Britain's Office of Financial Sanctions Implementation for breaching Russia sanctions in 2022. The bank processed two payments totaling approximately £635,619 to a Russian entity affiliated with a sanctioned entity in June and July 2022. The penalty was reduced by 45% from the original £300,000 fine after the bank self-reported the violations in September 2022.
- The violations involved two payments totaling around £635,619 processed to a Russian entity that had become affiliated with a sanctioned entity
- Deutsche Bank self-reported the payments in September 2022, qualifying for a 45% discount that reduced the penalty from £300,000 to £165,000
- The bank stated it 'takes sanctions compliance extremely seriously' and has strengthened its sanctions compliance framework and processes
UniCredit will not attend Commerzbank's annual shareholder meeting on Wednesday, maintaining a passive stance despite its ongoing takeover battle for the German lender. The decision comes at a critical point in the months-long dispute between UniCredit, which seeks control, and Commerzbank, which wants to remain independent.
- UniCredit CEO Andrea Orcel had previously stated in April that the bank had not decided on participation in the meeting
- The annual meeting occurs during a pivotal moment in the takeover tussle between the Italian and German lenders
- UniCredit declined to comment on its decision to skip the shareholder meeting
Shinsegae Group fired the CEO of Starbucks Korea after a promotional campaign called 'Tank Day' sparked public outrage by coinciding with the anniversary of the 1980 Gwangju pro-democracy uprising. The promotion's wording was seen as insensitive to victims of military violence during South Korea's fight against dictatorship, prompting an apology and swift executive action.
- The 'Tank Day' promotion launched on Democratisation Movement Day, the anniversary of the May 18, 1980 Gwangju uprising where hundreds or thousands were killed by military dictator Chun Doo-hwan's forces
- The campaign's wording recalled a former official's explanation for the 1987 death of a student protester later found to have been tortured, drawing connections to South Korea's authoritarian past
- South Korean President Lee Jae Myung publicly expressed being 'enraged' and demanded the company apologize to families of those killed during the uprising
Japan's economy grew at an annualized rate of 2.1% in Q1 2026, beating analyst expectations of 1.7% and improving from the previous quarter's 1.3% growth. The stronger-than-expected performance comes as the Bank of Japan has cut its full-year growth forecast and raised inflation projections due to rising crude oil prices from Middle East conflicts.
- Quarter-on-quarter growth was 0.5%, exceeding the 0.4% estimate and improving from 0.3% at the end of 2025
- The Bank of Japan cut its fiscal 2026 growth forecast to 0.5% from 1% while raising core inflation outlook to 2.8% from 1.9%, citing crude oil price increases
- The Q1 figures do not capture the full impact of the Iran war that began in late February, with economists warning of a potential 'stagflation-like situation' as real disposable incomes remain negative
Google I/O begins Tuesday as Alphabet seeks to demonstrate its AI leadership across the full technology stack, from custom chips to cloud infrastructure to consumer products. The company's stock has surged 140% over the past year, with cloud revenue growing 63% year-over-year and surpassing Azure and AWS growth rates. Investors are watching for updates on the next Gemini model, AI agents, agentic commerce, and external TPU chip sales.
- Google Cloud backlog reached $462 billion, up roughly 90% quarter-over-quarter, with generative AI product revenue growing approximately 800% year-over-year and the number of billion-dollar-plus deals in 2025 exceeding the previous three years combined.
- A potential Gemini 4 model announcement would position Google 'back up to the bleeding edge' against OpenAI and Anthropic, though analysts consider a Gemini 3.2 or 3.5 update more likely given the company's three-to-four month release cadence.
- Google plans to begin delivering its custom TPU AI chips to external customers in second half 2026, creating a new revenue stream in the estimated $500 billion AI chip market, while its $200 billion cloud commitment from Anthropic represents a significant portion of future contracted revenue.
U.S. crude oil futures dropped more than 2% in early Asian trading on Tuesday after President Trump paused a planned military strike on Iran to allow time for negotiations to end conflict in the Middle East. The decline reversed gains from the previous session as geopolitical tensions temporarily eased.
- WTI July contract fell $2.08 (2.02%) to $102.34 per barrel, while the front-month June contract dropped $1.54 (1.42%) to $107.12
- The decline followed Trump's announcement of pausing an Iran strike in favor of diplomatic negotiations
- Oil had gained over 3.1% in the previous session, suggesting markets had priced in heightened Middle East conflict risk
Germany's finance ministry has initiated a sales process for Uniper, the energy company nationalized during the 2022 European energy crisis, aiming to reduce the government's 99.12% stake to 25% plus one share. Interested parties have until June 12 to express interest. The sale or listing process is expected to be formalized before summer.
- Germany currently holds a 99.12% stake in Uniper after nationalizing the company during the 2022 energy crisis
- The sales process targets reducing government ownership to just 25% plus one share, with expressions of interest due by June 12
- The divestment will likely result in either a direct sale or public listing of the bailed-out energy firm
Bayer's Monsanto unit will pay at least $133 million to settle claims from Michigan and Rhode Island over PCB contamination of state natural resources. This brings Bayer's total PCB settlements to a dozen U.S. states as the company addresses legacy liabilities from chemicals Monsanto produced from 1935 to 1977. The settlement includes no admission of wrongdoing and could increase if Bayer succeeds in its lawsuit against former PCB buyers for indemnification.
- Michigan receives at least $108 million and Rhode Island at least $25 million, with potential additional payments of up to $176 million and $50 million respectively if Bayer wins its indemnification lawsuit against six legacy PCB buyers
- PCBs were widely used in electrical equipment, paper, caulking, and paint until banned by the U.S. government in 1979 due to links to cancer and other health problems
- Bayer acquired Monsanto for $63 billion in 2018 and has since faced extensive litigation over both PCBs and Roundup weedkiller claims across municipalities, states, schools, and individuals
French drugmaker Sanofi announced that its experimental rare disease therapy, efdoralprin alfa, outperformed standard care in a 97-patient trial for a genetic lung disease, raising key protein levels more effectively. The therapy, acquired through Sanofi's $2.2 billion Inhibrx deal in 2024, offers less frequent dosing and could help the company diversify beyond its top-selling drug Dupixent. Sanofi estimates about 235,000 people have the condition and sees opportunity in switching patients and reaching undiagnosed individuals.
- Efdoralprin alfa raised AAT protein levels by 24.1 micromolar at week 32 versus 7.6 micromolar for weekly standard therapy, with patients maintaining normal AAT levels throughout the study
- The therapy requires dosing only every three weeks compared to weekly for standard plasma-derived treatments, potentially easing treatment burden on patients
- Sanofi acquired the drug through its 2024 Inhibrx deal worth $2.2 billion following pipeline setbacks, as investors seek growth drivers beyond Dupixent
A U.S. jury ruled that Takeda Pharmaceutical caused approximately $885 million in damages to pharmacies, insurers, retailers, and other parties by delaying the release of a generic version of its constipation drug Amitiza through an anticompetitive scheme.
- The verdict holds Takeda liable for $885 million in damages across multiple affected parties including pharmacies, insurers, and retailers
- The case centered on allegations that Takeda engaged in an antitrust scheme to delay generic competition for Amitiza, its anti-constipation medication
- The jury's finding represents a significant legal loss for the Japanese pharmaceutical company in a U.S. antitrust case
Volvo Group will take a $197 million charge in Q2 2025 to settle allegations from California Air Resources Board regarding inadequate emission control descriptions on truck engines sold in California between 2010-2016. The settlement includes penalties, environmental project spending, and software updates for approximately 7,200 engines, with no admission of liability from Volvo.
- The settlement breaks down as: $13 million in civil penalties, $71 million to California's Air Pollution Control Fund, $108 million for emissions-reduction projects, and $5 million for CARB cost reimbursement
- Volvo will provide software updates and partial warranty extensions for about 7,200 affected engines in California as part of the agreement
- Operating cash-flow impact will be $89 million in the current quarter, with remaining payments spread over five years; the charge will be excluded from adjusted operating income
President Trump will announce a major expansion of TrumpRx.gov on Monday, adding generic medications to the government-backed discount drug website. Billionaire Mark Cuban, who runs Cost Plus Drugs online pharmacy, is expected to attend the White House event. The expansion is part of Trump's most-favored-nation deals with drugmakers aimed at lowering U.S. prescription costs to match other developed nations.
- TrumpRx.gov was originally launched in January as part of pricing agreements with pharmaceutical companies to reduce drug costs
- Despite Trump's pledge to make prescription drugs cheaper in the U.S. than anywhere else, a Reuters analysis found prices on the website are not lower than those in the United Kingdom
- Mark Cuban's Cost Plus Drugs, which already sells discounted medicines directly to consumers, will apparently play a role in the expanded program
BYD launched an upgraded version of its Denza N9 flagship SUV with a 5% price increase to 409,800 yuan ($60,265), marking the Chinese EV maker's continued push into premium markets and away from its low-cost image. The move comes as Denza faces intensifying competition from domestic rivals, with retail sales down 41.5% in the first four months of 2026 compared to the prior year. BYD is positioning Denza as key to its high-margin export strategy, having recently introduced the brand in Europe with actor Daniel Craig as brand ambassador.
- The new Denza N9 features over 100 upgrades including extended battery range and fast-charging capability, with a starting price of 409,800 yuan, up from 389,900 yuan for the previous model launched 14 months ago
- Denza claims 70% of its D9 buyers were former BMW, Mercedes-Benz, or Audi owners in China, though overall retail sales slumped 41.5% year-over-year in early 2026 due to competition from brands like Zeekr and Voyah
- BYD gained full ownership of Denza after Mercedes-Benz exited the joint venture in 2024, and is now betting on the premium brand to drive its high-margin export strategy in markets like Europe
Roche and the UN-backed Medicines Patent Pool signed a licensing agreement to expand access to flu drug Xofluza across 129 low- and middle-income countries. The deal allows generic manufacturers to produce the antiviral pill, aiming to boost supply during seasonal outbreaks and potential pandemics in regions with limited access to flu medicines.
- Generic drugmakers can now develop, manufacture and supply Xofluza across 129 low- and middle-income countries under the licensing agreement
- Xofluza is WHO-recommended and approved in the US and Europe, showing effectiveness against flu strains resistant to older antiviral classes
- Roche will provide licenses with data packages, reference products and regulatory support to accelerate generic development, while manufacturers handle their own approval processes
Uber Technologies has increased its ownership stake in Germany's Delivery Hero, according to an announcement made by Delivery Hero on Monday. The move strengthens Uber's position in the European food delivery market through its investment in one of the region's major players.
- Delivery Hero, a major German food delivery company, confirmed Uber has purchased additional shares
- The transaction reinforces Uber's strategic interests in international delivery markets beyond its core ride-hailing business
- This follows related news of Uber partnering with Naver on a potential Baemin takeover in South Korea
The U.S. Supreme Court on May 18 declined to hear challenges from six major pharmaceutical companies against Medicare's drug price negotiation program, which was established under Biden's 2022 Inflation Reduction Act. The decision leaves intact lower court rulings that rejected drugmakers' constitutional claims, allowing the program to continue under the Trump administration's defense.
- Six companies (Novo Nordisk, AstraZeneca, Janssen, Bristol Myers Squibb, Novartis, and Boehringer Ingelheim) had argued the program violates constitutional rights including Fifth Amendment protections and First Amendment free speech guarantees
- The first negotiated prices on 10 drugs went into effect in 2026, with the program requiring drugmakers to negotiate maximum prices with CMS or face steep daily excise taxes and potential withdrawal from Medicare programs
- The Trump administration is continuing to defend the Biden-era mechanism, with CMS Administrator Mehmet Oz citing it as part of efforts to reduce prescription drug costs for Medicare beneficiaries
The Supreme Court declined to hear Eli Lilly's challenge to the False Claims Act, a Civil War-era whistleblower law, leaving intact a $183 million judgment against the drugmaker for defrauding Medicaid. Lilly had argued the law unconstitutionally gives executive power to private citizens who can sue on behalf of the government. The decision preserves a law that recovered over $6.8 billion for the government in fiscal 2025.
- A federal jury found Lilly knowingly concealed retroactive drug price increases and failed to rebate Medicaid, resulting in $61 million in damages automatically tripled to $183 million under the False Claims Act
- The government recovered more than $6.8 billion through False Claims Act cases in fiscal 2025, with whistleblowers awarded over $330 million
- Lilly argued the law violates the Constitution by placing 'executive authority in the hands of private citizens with no meaningful supervision,' turning 'bounty hunters into ersatz executive officers'